Skip to main content
OpenTrials
Completed

NCT Number: NCT01428037

Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor

The purpose of this study is to estimate the efficacy and safety of the 25mcg vaginal misoprostol for cervical ripening and induction of labour.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

The First Affliated Hospital with Nanjing Meical Uniersity, Nanjing, Jiangsu, China

Loading trial locations.

About this study

There are many pregnant women require medical intervention to induce labor for some reasons at term. There are two fundamental changes that characterize pre-labor preparation for delivery: sensitization of the myometrium to produce contractions, and ripening (softening and dilation) of the cervix. A synthetic Prostaglandin misoprostol is fundamental to both of these changes. Low dose misoprostol is effective and safe for labor induction and has been used widely.

Oral tablets(200mcg) are broken into fragments and used intravaginally to ripen the cervix and induce labor due to the disadvantages of existing cervical ripeners (delivery of bolus doses, freezer or refrigerated storage, lack of efficacy in labor induction), and due to safety concerns with the off-label use of oral misoprostol tablet fragments, Regenex Corporation has developed a vaginal tablet with 25mcg misoprostol.

The primary objective of the study was to assess of the efficacy and safety of low dose (25 mcg) of misoprostol vaginal tablet for cervical ripening and induction of labour.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton pregnancy.
  • Aged 20 years or older.
  • At term (37 to 42 weeks inclusive gestation).
  • Cephalic presentation (normal lie).
  • No rupture.
  • Bishop score ≤6.
  • With an indication for labour induction.
  • Written informed consent.

Exclusion criteria

  • Any contraindication to vaginal delivery.
  • Previous of uterine scar(Cesarean section or other uterine surgeries).
  • Heavy or repeated vaginal bleeding in third trimester of pregnancy.
  • Have a history of glaucoma,asthma or epilepsy.
  • Contraindication to prostaglandin use.
  • Known severe allergy to prostaglandin.
  • Placenta previa
  • Premature rupture of membranes
  • Placental abruption
  • Fetal malpresentation(Breech or Transverse)
  • Obvious cephalopelvic disproportion
  • Amniotic Fluid Index more than 250mm or less than 50mm
  • Fetal growth restriction
  • Fetal malformation
  • Fetal distress
  • Preeclampsia or eclampsia
  • Fetal macrosomia of prenatal diagnosis(B-type ultrasonic inspection/Abdomen estimates)
  • Intrahepatic cholestasis syndrome(ICP)
  • Pregnancy with severe heart, lung, liver, kidney, endocrine disease and immune dysfunction
  • Pregnancy with acute systemic infection
  • Pregnancy with Severe anemia
  • Cervical carcinoma
  • Some genital tract infection disease, such as active herpes infection
  • Take part in other clinical trials within three months.
  • The person that investigator thought not be enrolled.

Treatment and study plan

Placebo

Drug

One tablet vaginal inserted at 4 hrly interval with maximum of three doses

Misoprostol vaginal Tablet 25 mcg

Drug

One tablet vaginal insert at 4 hrly interval with maximum of three doses

Other names: Misoprostol vaginal Tablet

Primary outcomes

  1. Treatment success rate

    Time frame: From the first dose to 12-24 hours

    Treatment success is defined as: ≧3 of Bishop score increased within 12 hours or Vaginal delivery within 24 hours.

Secondary outcomes

  1. Percentage of participants of labor onset within 24 hours

    Time frame: From the first dose to 24 hours

  2. Time from 1st dose to labor onset

    Time frame: From the first dose to labor onset

  3. Need for augmentation of labor with oxytocin

    Time frame: From the first dose to neonate delivery

  4. Rate and reason for Cesarean Section

    Time frame: From the first dose to neonate delivery

Sponsors and collaborators

Lead sponsor

Regenex Pharmaceutical, China

Other

Registry information

Official study title

A Randomized,Double-blind,Placebo-controlled, Multicenter Study of the Efficacy and Safety of Vaginal Misoprostol for Cervical Ripening and Induction of Labor

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Sep 2, 2011
Registry last updated
Nov 25, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.